MENLO PARK, Calif., Dec. 4, 2017 /PRNewswire/ -- BioPharmX
Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share
research suggesting that BPX-01, the company's topical gel formulation of minocycline, may exhibit relevant antimicrobial and
anti-inflammatory properties for the treatment of acne. Data from cellular analysis shows minocycline's effectiveness may be due
to its antimicrobial effect and its ability to modulate the effects of pro-inflammatory cytokines associated with acne
pathology.
BioPharmX will share its findings in a poster entitled "BPX-01 Topical Minocycline Gel Reduces P. acnes-Induced
Inflammatory Lesions in Mice" today at a conference hosted by the American Society for Cell Biology (ASBC) and European Molecular
Biology Organization (EMBO) in Philadelphia, the company's first presentation of these data to
the cellular biology community.
Study findings show that minocycline has anti-inflammatory activities in in vitro and animal models. Researchers
identified two markers, cytokine IL-1 alpha and IL-6. P. acnes of inflammatory cytokine IL-1 alpha secretion in
human keratinocytes. Researchers found that minocycline can decrease stimulated IL-1 alpha secretion and modulate the production
of IL-6 in keratinocytes.
"Antibiotic resistance to topical clindamycin has become more prevalent in acne patients," said Kin F. Chan, executive vice
president of research and technology at BioPharmX. "The development of a topical minocycline gel may provide an alternative with
significant therapeutic benefits that are currently only available through the use of an oral formulation, which exposes patients
to the risk of adverse side effects."
The 2017 ASCB/EMBO meeting is the largest gathering of cell scientists. The meeting is expected to attract 6,000
attendees from around the world.
About BPX-01
BPX-011 is a hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that has been shown to
penetrate the skin to deliver the antibiotic to its target. Following positive results from its previously announced phase
2b study of BPX-01 in acne, BioPharmX continues with phase 3 clinical study plans for BPX-01 for
the treatment of acne.
About BioPharmX Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide
products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the
health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to
the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's
expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the safety and medical
effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the commencement and results of future trials of BPX-01
and the size of such trials, continued and consistent results in future tests of BPX-01 and absence of side effects of future use
of BPX-01. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or
similar expressions that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such
forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and
Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017 and our quarterly report on
Form 10-Q for the period ended July 31, 2017. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news
release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under
applicable securities law.
1 Caution: BPX-01 is a new drug limited by U.S. law to investigational use.
View original content with multimedia:http://www.prnewswire.com/news-releases/biopharmx-demonstrates-topical-minocycline-gel-may-exhibit-relevant-antimicrobial-and-anti-inflammatory-properties-for-the-treatment-of-acne-at-ascb-2017-300565743.html
SOURCE BioPharmX Corporation